Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells $2,019,530.16 in Stock

by · The Cerbat Gem

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) EVP Scott Dreyer sold 49,976 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the transaction, the executive vice president directly owned 71,770 shares in the company, valued at $2,900,225.70. The trade was a 41.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Scott Dreyer also recently made the following trade(s):

  • On Monday, December 8th, Scott Dreyer sold 17,600 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $48.17, for a total value of $847,792.00.

Collegium Pharmaceutical Trading Down 5.9%

Shares of Collegium Pharmaceutical stock traded down $2.33 during trading hours on Thursday, reaching $37.28. 902,832 shares of the company’s stock were exchanged, compared to its average volume of 453,803. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $50.79. The company has a fifty day moving average of $45.98 and a 200-day moving average of $42.12. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59. The firm has a market capitalization of $1.18 billion, a price-to-earnings ratio of 21.80 and a beta of 0.67.

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). Collegium Pharmaceutical had a return on equity of 98.65% and a net margin of 8.05%.The business had revenue of $205.45 million during the quarter, compared to analyst estimates of $206.36 million. During the same period in the previous year, the business posted $1.77 earnings per share. The firm’s quarterly revenue was up 12.9% on a year-over-year basis. Sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on COLL. Weiss Ratings reissued a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Barclays reduced their price objective on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a research note on Friday, January 9th. Truist Financial set a $58.00 target price on Collegium Pharmaceutical in a report on Tuesday, February 10th. Needham & Company LLC dropped their target price on shares of Collegium Pharmaceutical from $56.00 to $54.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price target (up from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Five equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus price target of $53.00.

Read Our Latest Analysis on Collegium Pharmaceutical

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Collegium Pharmaceutical by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after buying an additional 825 shares during the period. Millennium Management LLC grew its stake in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after acquiring an additional 461,914 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Collegium Pharmaceutical by 7.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after acquiring an additional 4,625 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Collegium Pharmaceutical by 218.7% in the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock worth $3,926,000 after acquiring an additional 90,255 shares in the last quarter. Finally, CWM LLC boosted its holdings in Collegium Pharmaceutical by 453.9% in the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 1,153 shares during the last quarter.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

Further Reading